PLAUR and hematologic disorder: However, despite an abundance of literature demonstrating the importance of uPAR in the progression of most solid cancers, including breast [18], colon [19], prostate [20], pancreatic [21], ovarian [22], lung [23], and brain [24] as well as several hematologic malignancies such as acute leukemia and myeloma [25], no uPAR targeted therapeutic agent has been developed or evaluated in cancer clinical trials to date.